Cargando…

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commonly used subcutaneous injection sites (abdomen, up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotani, Naoki, Yoneyama, Koichiro, Kawakami, Nobuhiko, Shimuta, Tohru, Fukase, Hiroyuki, Kawanishi, Takehiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767117/ https://www.ncbi.nlm.nih.gov/pubmed/30230257 http://dx.doi.org/10.1002/cpdd.617

Ejemplares similares

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2017)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2014)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2021)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
por: Shima, Midori, et al.
Publicado: (2019)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

The stable isotope method for determining absolute bioavailability
por: Atkinson, Arthur J.
Publicado: (2017)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

The dosing conundrum of emicizumab: To waste product or not?
por: Young, Guy
Publicado: (2023)

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid
por: Flanagan, Shawn, et al.
Publicado: (2014)

The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for Cats(®)) in Cats
por: Kong, Jingyuan, et al.
Publicado: (2023)

Bioavailability and feasibility of subcutaneous 5-fluorouracil.
por: Borner, M. M., et al.
Publicado: (1993)

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
por: Babonneau, Jérémie, et al.
Publicado: (2019)

Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Absolute oral bioavailability and disposition kinetics of puerarin in female rats
por: Anukunwithaya, Tosapol, et al.
Publicado: (2018)

Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals
por: Kvitne, Kine Eide, et al.
Publicado: (2023)

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017)

Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment
por: Holmes, Eric H., et al.
Publicado: (2013)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers
por: Inoue, Yushi, et al.
Publicado: (2012)

Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers
por: BRICIU, CORINA, et al.
Publicado: (2015)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
por: Johne, Andreas, et al.
Publicado: (2020)

Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth
por: Alraddadi, Eman A., et al.
Publicado: (2018)

Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia
por: Hu, Jun-Hao, et al.
Publicado: (2019)

The ICU Bridge Program: volunteers bridging medicine and people together
por: Petrecca, Sarah, et al.
Publicado: (2022)

Hospice volunteers: bridging the gap to the community?
por: Morris, Sara M., et al.
Publicado: (2015)

Bioavailability of a Lipidic Formulation of Curcumin in Healthy Human Volunteers
por: Pawar, Yogesh B., et al.
Publicado: (2012)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
por: Donners, Anouk A. M. T., et al.
Publicado: (2021)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qk427u89d926e9bm0165v3ieft